Biomarkers of cholestasis.
biomarker
cholestasis
liver
omics
Journal
Biomarkers in medicine
ISSN: 1752-0371
Titre abrégé: Biomark Med
Pays: England
ID NLM: 101312535
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
pubmed:
13
3
2021
medline:
3
2
2022
entrez:
12
3
2021
Statut:
ppublish
Résumé
Cholestasis is a major pathological manifestation, often resulting in detrimental liver conditions, which occurs in a variety of indications collectively termed cholestatic liver diseases. The frequent asymptomatic character and complexity of cholestasis, together with the lack of a straightforward biomarker, hampers early detection and treatment of the condition. The 'omics' era, however, has resulted in a plethora of cholestatic indicators, yet a single clinically applicable biomarker for a given cholestatic disease remains missing. The criteria to fulfil as an ideal biomarker as well as the challenging molecular pathways in cholestatic liver diseases advocate for a scenario in which multiple biomarkers, originating from different domains, will be assessed concomitantly. This review gives an overview of classical clinical and novel molecular biomarkers in cholestasis, focusing on their benefits and drawbacks.
Identifiants
pubmed: 33709780
doi: 10.2217/bmm-2020-0691
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM